Developing a vaccine to prevent syphilis using outer membrane proteins.
A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum
['FUNDING_U01'] · DUKE UNIVERSITY · NIH-11077819
This study is working on a new vaccine to help prevent syphilis by focusing on certain proteins from the bacteria that cause it, and if successful, it could offer protection for people at risk of this infection.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11077819 on ClinicalTrials.gov |
What this research studies
This research aims to create a vaccine against syphilis by targeting specific proteins found in the outer membrane of the Treponema pallidum bacteria. The approach combines advanced techniques in bioinformatics and biophysics to identify and characterize these proteins, which are believed to be crucial for eliciting a protective immune response. The project will involve preclinical studies in animal models to test the effectiveness of the vaccine before moving to human trials. Patients may benefit from this research if the vaccine proves effective in preventing syphilis infections.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals at high risk for syphilis infection, such as those in certain geographic areas or with specific behavioral risk factors.
Not a fit: Patients who are already infected with syphilis or those who do not have risk factors for syphilis may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of syphilis and its associated health complications.
How similar studies have performed: Other research has shown promise in developing vaccines targeting similar bacterial outer membrane proteins, indicating a potential for success in this approach.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MOODY, MICHAEL ANTHONY — DUKE UNIVERSITY
- Study coordinator: MOODY, MICHAEL ANTHONY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.